Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line

References

• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124.
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–2111.
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26:5422–5428.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–1068.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722–731.
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Cartenì G, Sternberg CN, et al. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. Eur J Cancer. 2013;49:2134–2142.
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl. 3):iii49–iii56.
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67:913–924.
   PubMed Web of Science ®Google Scholar
• NCCN. NCCN guidelines. Kidney cancer [Internet; cited 2015 Dec 23]. Available from: www.nccn.org/professionals/physician_gls/PDF/kidney.pdf
   Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–456.
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–1939.
   PubMed Web of Science ®Google Scholar
• Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32:760–767.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116:4256–4265.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results of a randomized phase 3 trial. Lancet Oncol. 2013;14:552–562.
   PubMed Web of Science ®Google Scholar
• Calvo E, Escudier B, Motzer RJ, et al. Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer. 2012;48:333–339.
   PubMed Web of Science ®Google Scholar
• Escudier B, Michaelson MD, Motzer RJ, et al. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer. 2014;110:2821–2828.
   PubMed Web of Science ®Google Scholar
• Eichelberg C, Vervenne WL, De Santis M, et al. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer. Eur Urol. 2015 May 4. pii: S0302-2838(15)00319-X. DOI:10.1016/j.eururo.2015.04.017. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32:2765–2772.
   PubMed Web of Science ®Google Scholar
• Stenner F, Chastonay R, Liewen H, et al. A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. Oncology. 2012;82:333–340.
   PubMed Web of Science ®Google Scholar
• Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220–231.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Alyasova A, Ye D, et al. RECORD-4: a multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2015;33(suppl.):abstr. 4518.
   PubMed Web of Science ®Google Scholar
• Grunwald V, Karakiewicz PI, Bavbel SE, et al. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur Urol. 2012;48:324–332.
   Google Scholar
• Paglino C, Procopio G, Sabbatini R, et al. A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer. Anticancer Res. 2013;33:4999–5004.
   PubMed Web of Science ®Google Scholar
• Kumano M, Miyake H, Harada K, et al. Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors. Med Oncol. 2013;30:745.
   PubMed Web of Science ®Google Scholar
• Busch J, Seidel C, Erber B, et al. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma. Eur Urol. 2013;64:62–70.
   PubMed Web of Science ®Google Scholar
• Calvani N, Morelli F, Chiuri V, et al. Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike? Med Oncol. 2013;30:578.
   PubMed Web of Science ®Google Scholar
• Albiges L, Kube U, Eymard JC, et al. Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: updated results of a pooled analysis of noninterventional studies. Ann Oncol. 2014;25(Suppl. 4):iv294.
   Google Scholar
• Hutson T, Hackshaw MD, Vogelzang N, et al. Outcomes of advanced renal cell carcinoma patients (ARCC) treated with mammalian target of rapamycin inhibitor (MTOR) therapy following first-line pazopanib (PAZ) in a US Community Oncology setting. Ann Oncol. 2014;25(Suppl. 4):iv295 (abstr. 847P).
   Google Scholar
• Buchler T, Bortlicek Z, Poprach A, et al. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis. Urol Oncol. 2014;32:569–575.
   PubMed Web of Science ®Google Scholar
• Bergmann L, Kube U, Doehn C, et al. Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study. BMC Cancer. 2015;15:303.
   PubMed Web of Science ®Google Scholar
• Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009;27:4462–4468.
   PubMed Web of Science ®Google Scholar
• Vogl UM, Ponhold L, Locker GJ, et al. Safety and efficacy of axitinib in sorafenib-refractory metastatic renal cell carcinoma: a single center experience of the Medical University of Vienna, Austria. J Clin Oncol. 2013;31(Suppl.):abstr. e15535.
   PubMed Web of Science ®Google Scholar
• Matias M, Albiges L, Lassau N, et al. Efficacy of axitinib in renal cell carcinoma: real-world experience at Gustave Roussy (IGR). J Clin Oncol. 2014;32(Suppl.):abstr e15593.
   Google Scholar
• Maroto P, Lainez N, Esteban E, et al. Real life efficacy and safety of axitinib (AXI) in patients with renal cell carcinoma (RCC): results from the Spanish Compassionate Use Program. Ann Oncol. 2014;25(Suppl. 4):iv304.
   Google Scholar
• Albiges L, Choueiri TK, Escudier B, et al. A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. Eur Urol. 2015;67:100–110.
   PubMed Web of Science ®Google Scholar
• Al-Marrawi MY, Rini BI, Harshman LC, et al. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol. 2013;8:203–209.
   PubMed Web of Science ®Google Scholar
• Heng DY, Mackenzie MJ, Vaishampayan UN, et al. Primary antivascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol. 2012;23:1549–1555.
   PubMed Web of Science ®Google Scholar
• Elaidi R, Harbaoui A, Beuselinck B, et al. Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma. Ann Oncol. 2015;26:378–385.
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Imarisio I. Sorafenib rechallenge in metastatic renal cell carcinoma. BJU Int. 2012;110:E235.
   PubMed Web of Science ®Google Scholar
• Escudier B, Szczylik C, Porta C, et al. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol. 2012;9:327–337.
   PubMed Web of Science ®Google Scholar
• Bracarda S, Sisani M, Marroccolo F, et al. GOAL: an inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer. Crit Rev Oncol Hematol. 2014;89:386–393.
   PubMed Web of Science ®Google Scholar
• Porta C. Entropy increases in kidney cancer treatment, but a bit of simplicity may emerge from chaos. Eur Urol. 2011;60:1171–1172.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:286–296.
   PubMed Web of Science ®Google Scholar
• Porta C, Giglione P, Liguigli W, et al. Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity. Future Oncol. 2015;11:39–50.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Buonerba C, Federico P, et al. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol. 2010;58:906–911.
   PubMed Web of Science ®Google Scholar
• Pal SK, Hossain DM, Zhang Q, et al. Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile. J Urol. 2015;193:1114–1121.
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Farcomeni A, Sternberg CN, et al. Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. J Urol. 2015;193:1905–1910.
   PubMed Web of Science ®Google Scholar
• Stenner-Liewen F, Grunwald V, Greil R, et al. The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2013;13:1021–1033.
   PubMed Web of Science ®Google Scholar
• Heng DYC, Wells C, Donskov F, et al. Third-line therapy in metastatic renal cell carcinoma: results from the International mRCC Database Consortium. J Clin Oncol. 2015;33(Suppl.):abstr. 430.
   Google Scholar
• Vallet S, Pahernik S, Höfner T, et al. Efficacy of targeted treatment beyond third-line therapy in metastatic kidney cancer: retrospective analysis from a large-volume cancer center. Clin Genitourin Cancer. 2015;13:e145–152.
   Google Scholar
• Zama IN, Hutson TE, Elson P, et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer. 2010;116:5400–5406.
   PubMed Web of Science ®Google Scholar
• Nozawa M, Yamamoto Y, Minami T, et al. Sorafenib rechallenge in patients with metastatic renal cell carcinoma. BJU Int. 2012;110:E228–234.
   Google Scholar
• Grunwald V, Weikert S, Seidel C, et al. Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC. Onkologie. 2011;34:310–314.
   PubMedGoogle Scholar
• Park I, Lee JL, Ahn JH, et al. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor. Cancer Chemother Pharmacol. 2015;75:1025–1035.
   PubMed Web of Science ®Google Scholar
• Paule B, Brion N. Sunitinib re-challenge in metastatic renal cell carcinoma treated sequentially with tyrosine kinase inhibitors and everolimus. Anticancer Res. 2011;31:3507–3510.
   PubMed Web of Science ®Google Scholar
• Oudard S, Gross Goupil M, Geoffrois L, et al. Clinical activity of sunitinib rechallenge in metastatic Renal Cell Carcinoma – results of the RESUME study. Ann Oncol. 2014;25(Suppl.):abstr. 816PD.
   Google Scholar
• Maj-Hes A, Medioni J, Scotte F, et al. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy. Oncology. 2013;85:8–13.
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Grunwald V. Sunitinib re-challenge in advanced renal cell carcinoma. Br J Cancer. 2014;111:1047–1053.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015. DOI:10.1056/NEJMoa1510016.
   Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015. DOI:10.1056/NEJMoa1510665.
   Web of Science ®Google Scholar
• Vogelzang NJ. Treatment options in metastatic renal carcinoma: an embarrassment of riches. J Clin Oncol. 2006;24:1–3.
   PubMed Web of Science ®Google Scholar
• Porta C, Bellmunt J, Eisen T, et al. Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat Rev. 2010;36:16–23.
   PubMed Web of Science ®Google Scholar
• Voss MH, Hakimi AA, Pham CG, et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res. 2014;20:1955–1964.
   PubMed Web of Science ®Google Scholar
• Fay AP, Kwiatkowski DJ, Gray KP, et al. Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): results from a large multi-institutional cohort. J Clin Oncol. 2015;33(Suppl.):abstr. 4519.
   Google Scholar
• Powles T. Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns. Clin Genitourin Cancer. 2012;10:67–68.
   PubMed Web of Science ®Google Scholar